26Aug 2023
Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker

Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker

This study investigates pharmacodynamic responses to SGLT2 inhibitors and their genetic connections in a canagliflozin pilot study involving healthy volunteers. Acute changes in biomarkers are observed, with potential sex-related responses under data normalization. This approach aids genetic association discovery with reduced confounding factors in ongoing studies involving healthy individuals.

  • #general medicine

Like

Save

Share